ARTICLE | Company News
CeNes licenses Moraxen to Amarin
January 4, 2001 8:00 AM UTC
CeNes (LSE:CEN) granted AMRN exclusive North American marketing rights to Moraxen controlled release morphine hydrogel for severe cancer pain. CEN will receive an upfront fee, plus royalties. Moraxen ...